Press Release Details

Title
08 Jan 2008

Bharat Biotech Announces the visit of the Honourable Secretary of the United States Department of Health and Human Services, Michael O. Leavitt to its facilities at Genome Valley, Hyderabad

Details

Bharat Biotech Announces the Launch of BioHib, India’s First Haemophilus Influenza type b Vaccine Developed with Indigenous Technology

Genome Valley, Hyderabad - September 3rd 2007: India’s most pioneering biotechnology company, Bharat Biotech International Limited (BBIL) announces the launch of BioHib, the first indigenously developed and manufactured Haemophilus Influenza type b (Hib) vaccine in India. BioHib is a conjugate vaccine that has proven its safety and efficacy in multi-centric clinical trials. BioHib is a safe and efficacious vaccine developed with conjugation and manufacturing technologies developed at Bharat Biotech. BioHib will be a safe and affordable vaccine that offers complete protection against Hib infections.

Haemophilus influenza type b (Hib) bacterium causes serious disease, often life-threatening illnesses in young children. Hib can cause meningitis and severe pneumonia, leading to ~3 million cases of serious illness and 400,000 deaths each year in children under 5 years of age. Hib is difficult to treat in the developing world, with infected children in developing countries are several times worse than those in industrialized countries. Invasive disease can be treated with antibiotics but lack of access to adequate medical facilities and increasing levels of antibiotic resistance lead to a high mortality rate: 20% of children in developing countries with Hib meningitis will die (rising to an even higher percentage in Africa and Asia). 15%-35% of children suffering from Hib meningitis will go on to develop life long disabilities such as mental retardation or hearing loss.

The scientific and product development teams at Bharat Biotech take pride in their efforts to develop and commercialize BioHib. While other Indian manufacturers have imported conjugation and manufacturing technologies from Europe, and USA, the scientific, manufacturing and product development teams at Bharat Biotech have completely developed all processes required to manufacture BioHib in-house at Bharat Biotech. Bharat Biotech has made significant investments to the tune of several million $ over the past 4 years, into its R&D; capabilities and its manufacturing facilities to enable the development and manufacture of BioHib.

Bharat Biotech also announces the launch of its tetravalent combination vaccine, Comvac4-HB containing Diphtheria, Pertussis, Tetanus and Hepatitis B in one vaccine. These two new vaccines BioHib and Comvac4-HB, enable the deployment of a combination pentavalent vaccine in a single injection.

“The launch of BioHib is a significant milestone for Bharat Biotech and more importantly for India, since all technologies were developed within India. BioHib has the ability to save the lives of millions of children worldwide at a very affordable price. The tetravalent and pentavalent vaccines give us the ability to protect children against multiple infectious diseases with a single injection. BioHib and Comvac4-HB are the latest offerings from Bharat Biotech in its commitment to develop safe and affordable vaccines for the developing world” said Dr. Krishna M. Ella, Chairman and Managing Director of Bharat Biotech.

About Bharat Biotech International Limited Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech was established in
the year 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat Biotech is one of the first bio-pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA). Bharat Biotech sprawls over a picturesque campus at Genome Valley, Hyderabad, built with an investment of over USD 100 million, the facility’s Manufacturing, Control Procedures and Protocols, conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO. Bharat has set new benchmarks in Innovation and Quality that epitomizes the tremendous progress of Indian biotechnology in the global arena. Bharat Biotech is the largest primary manufacturer of Vi Capsular Polysaccharide Typhoid vaccine, TYPBAR®, the first to manufacture, INDIKINASE™, a recombinant Streptokinase and BIOGIT™, a yeast based probiotic yeast product in India. Bharat Biotech has commercialized India’s first recombinant Epidermal Growth Factor, REGEN-D™ to combat diabetic foot ulcers, burns. Bharat Biotech’s INDIRAB™ (anti-rabies vaccine) is a market leader in protection against rabies infections from dog bites. Bharat Biotech has a strong pipeline of vaccines to combat Malaria, Rotavirus and Japanese Encephalitis infections.